[Longevity Dispatch] 🔬 3 Longevity Breakthroughs That Just Changed What We Know About Aging (June 2026)
News from the longevity, biohacking, health, and supplement fronts.
By Valérie Orsoni — Biohacker & Longevity Expert
Valérie Orsoni is a biohacker, author of 56 books, and founder of biohacker.fr. She has been tracking her biology through N=1 self-experimentation protocols since 1998. She is currently enrolled in Stanford Medicine’s longevity research certification program.
Week of June 14th, 2026 — ValBiohacker.com
🧠 Your Gut Microbiome May Be Aging Your Brain
What if the bacteria living in your gut were the hidden enemy of your cognition?
That’s the provocative conclusion of a Harvard study published in February 2026 by Dr. Lee Rubin’s lab (Department of Stem Cell and Regenerative Biology, Harvard / Broad Institute of MIT). The findings are counter-intuitive — and they could reshape the way we approach brain health after 50.
What the researchers did:
Aged mice were given a cocktail of antibiotics (ampicillin, neomycin, vancomycin, and metronidazole) for 30 days to deplete their gut microbiome. The result? Their brains started behaving like those of young individuals.
What concretely changed:
→ Significant improvement in memory and learning ability (novel object recognition test)
→ Higher levels of neuronal activation
→ Increased neurogenesis — the production of new neurons
→ Reduced chronic brain inflammation
→ Lower burden of senescent cells in the brain
⚠️ What this does NOT mean:
These results do not mean probiotics are useless or harmful. The study was conducted in aged mice under conditions of total microbiome depletion — a scenario that cannot be directly extrapolated to humans. What’s really at issue is the progressive accumulation of pro-inflammatory bacteria with age, at the expense of beneficial species that produce protective metabolites like butyrate.
The real message:
An aged microbiome doesn’t just “lack” good bacteria. It actively produces metabolites that accelerate brain aging.
Microbiome composition starts shifting as early as mid-life. Pro-inflammatory species proliferate, crowding out the ones that produce neuroprotective compounds. The good news: this opens the door to targeted interventions — not necessarily antibiotics, but strategies aimed at restoring a “younger” microbiome through diet, prebiotics, or fecal microbiota transplantation (FMT).
What to take away for practice:
→ Daily fermentable fibers (inulin, FOS, resistant starch) to feed beneficial species
→ Limit microbiome disruptors: long-term antibiotics, ultra-processed foods, alcohol
→ Keep a close eye on FMT and postbiotic research — this field is moving fast
📌 Reference: Gasperini et al., 2026 — bioRxiv (pre-print). Funded by NIH/National Institute on Aging + Simons Foundation.
💊 Rapamycin & Longevity: The Largest Human Trial Ever Just Launched
The most promising molecule in geroscience is finally being tested at human scale.
For over 15 years, rapamycin has fascinated longevity researchers. It is, to date, the molecule that most consistently and reproducibly extends lifespan in mice — across sexes, doses, and independent laboratories. But what about humans?
The mechanism, briefly:
Rapamycin inhibits mTORC1, a central protein complex that regulates cell growth, metabolism, and aging. At low, intermittent doses, it does not suppress the immune system — it may actually rejuvenate it by restoring immune functions that aging progressively erodes.
Where does the human data stand?
The PEARL Trial (AgelessRx, 48 weeks, double-blind, randomized placebo-controlled, n=114 participants, average age ~60) delivered in 2025 the first controlled data on healthy adults:
→ Improvement in lean muscle mass
→ Improvement in bone mineral density
→ Favorable trend on visceral fat
→ Satisfactory safety profile at tested doses (5 and 10 mg/week)
→ No significant difference in adverse events vs. placebo
⚠️ Important caveat: the compounded rapamycin used in the trial had roughly 3× lower bioavailability than the commercial form (sirolimus). This limits interpretation of the efficacy results.
The big news from April 2026:
The largest human rapamycin trial ever conducted has just been launched. Designed to answer the fundamental questions still unanswered — what dose, what duration, which patient profile benefits most — this trial aims to generate the large-scale, long-duration, deeply phenotyped human data the field has been missing.
The honest verdict as of today:
The animal data is remarkably consistent. The early human data is encouraging but insufficient to support firm clinical recommendations.
Off-label use is growing rapidly in longevity clinics, but without standardized dosing or established long-term safety data. If you’re considering rapamycin, this is a decision to make with a specialized physician, with full awareness of the current level of evidence.
What to watch:
→ Results of the 2026 large-scale trial (duration, deep phenotyping)
→ Comparison of rapamycin vs. GLP-1 + rapamycin in combination
→ Development of mTOR analogs with improved selectivity profiles
📌 References: PEARL Trial — Moel et al., Aging, April 2025; Healthspan.com, April 2026.
🧫 Senolytics: “Killing” Your Zombie Cells to Rejuvenate Your Tissues
Your body is accumulating cells that refuse to die — and that poison everything around them.
Senescent cells are cells in a permanent state of cell cycle arrest. They no longer divide, no longer function normally, but remain present in tissues and continuously secrete a toxic cocktail of pro-inflammatory cytokines, remodeling enzymes, and lipid mediators. This behavior is called the SASP (Senescence-Associated Secretory Phenotype).
The result: a silent, chronic low-grade inflammation that builds with age, accelerating the progression of neurodegenerative, cardiovascular, metabolic, and joint diseases.
Two drug classes on the rise:
→ Senolytics: actively eliminate senescent cells by triggering apoptosis
→ Senomorphics: don’t kill the cells, but inhibit SASP secretion
The most studied duo: Dasatinib + Quercetin (D+Q)
Dasatinib is an FDA/EMA-approved cancer drug (chronic myeloid leukemia). Quercetin is a natural flavonoid found in onions, capers, and apples. Together, they disable the anti-apoptotic survival pathways that allow senescent cells to persist.
Striking preclinical results (aged mice):
→ 36% reduction in post-treatment mortality
→ 65% reduction in risk of death
→ Attenuation of physical frailty
→ Delayed onset of age-related diseases
→ Improved metabolic function (insulin sensitivity, adipose tissue inflammation)
The first human clinical trials:
Early-phase clinical trials have targeted conditions with a strong senescence component:
→ Idiopathic pulmonary fibrosis (IPF) — confirmed improvement in physical function
→ Diabetic kidney disease — reduction of senescence markers in tissues
→ Systemic sclerosis — reduction of SASP in skin biopsies
⚠️ What to know before you think about “trying” this:
Dasatinib is a chemotherapy drug with real side effects.
Quercetin as a standalone supplement has highly variable bioavailability. Clinically tested protocols use short intermittent cycles (e.g. 3 days/month), not daily intake.
No trial has yet been conducted on healthy individuals for prevention purposes.
What comes next:
Research is now moving toward more selective senolytics with fewer off-target effects. Nanoparticle-based approaches specifically targeting lysosomal β-galactosidase (overexpressed in senescent cells) are showing promising preclinical results.
Clearing zombie cells could be one of the most impactful anti-aging interventions of the next decade — if human trials confirm what mice have been showing us for 10 years.
What to take away for practice:
→ Dietary quercetin: red onions, capers, organic apples with skin (most bioavailable form)
→ Intermittent fasting and caloric restriction: activate clearance of dysfunctional cells via autophagy
→ High-intensity exercise: reduces accumulation of senescent cells in muscles
→ Monitor ongoing trials at clinicaltrials.gov (search: “senolytics”)
📌 References: Zhu et al., Nature Medicine; Kirkland et al., Mayo Clinic; Islam et al., Aging Cell, 2023; Maurer et al., Aging Cell, 2024.
Let’s keep going! Forza!
Valérie Orsoni
Biohacker since 1998 | Longevity Expert
Instagram : Valerie Orsoni
My fave brands + super promo codes here ==> ValerieOrsoni.com
My made-in-the-usa, clean, no fillers supplement line ==> ZellNova
🎙 Life Summit— Berlin (29-30 mai 2026)
🎙 Corsica Biohacking — Corsica (6-13 juin 2026)
🎙 Biohackers World Conference — New York (juin 2026)
🎙 RAADFest— Sedona (4-6 septembre 2026)
🎙 HealthSpan Summit — Los Angeles (2–4 oct. 2026)
🎙 Reclaiming Health & Longevity Symposium — El Salvador (8–9 nov. 2026)